Fennec Pharmaceuticals Engages with Investors at Upcoming Conferences
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a committed participant in the specialty pharmaceutical sector, is gearing up to attend several investor conferences. During these events, the company's management will also conduct one-on-one meetings, providing a valuable chance to connect with investors and share important updates.
Highlights of Upcoming Conferences
Below are the details of the significant conferences where Fennec Pharmaceuticals will be represented:
H.C. Wainwright Global Investment Conference
Date: September 11, 2024
Time: Presentation from 12:00 p.m. to 12:30 p.m. ET
Location: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor
Cantor Fitzgerald Global Healthcare Conference
Date: September 19, 2024
Time: Fireside chat from 8:35 a.m. to 9:05 a.m. ET
Location: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1
These conferences serve as essential platforms for the company to connect with both current and prospective investors, offering insights into its strategic initiatives and ongoing projects.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals is dedicated to innovation within the pharmaceutical industry, particularly through its leading product, PEDMARK. This treatment is designed to address the risks of platinum-induced ototoxicity, especially in young patients. Following its FDA approval in 2022, PEDMARK also received approval from the European Commission in 2023, with U.K. authorization following shortly thereafter. Known as PEDMARQSI in Europe, this product has secured a strong marketing position, benefiting from Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, which ensures extensive data protection in these regions.
Contact Information for Inquiries
If you need further information about Fennec Pharmaceuticals, please reach out to:
Investors
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate & Media Inquiries
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
Frequently Asked Questions
What is Fennec Pharmaceuticals known for?
Fennec Pharmaceuticals focuses on developing treatments aimed at reducing the risk of ototoxicity in pediatric patients.
When is Fennec participating in the H.C. Wainwright conference?
Fennec will present at the H.C. Wainwright Global Investment Conference on September 11, 2024.
How can investors contact Fennec Pharmaceuticals?
Investors can get in touch with Robert Andrade, the Chief Financial Officer, at +1 919-246-5299.
What recent approvals has PEDMARK received?
PEDMARK was granted FDA approval in September 2022, followed by European approval in June 2023, and U.K. approval in October 2023.
Why is Fennec's participation in these conferences important?
These conferences provide Fennec with the opportunity to directly engage with investors, offering important updates on its strategic direction and product advancements.